#rapamycin

• Topical rapamycin reduces markers of senescence and aging in human skin 20260516215632000
• PMID 38310895 20260516215523000
• mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis 20260516213747000
• Targeting ageing with rapamycin and its derivatives in humans: a systematic review. 20260516202605000
• mTOR 20260509193615000
• 17-alpha estradiol 的严格复现网络边界 20260427013238000
• FGF21 成年哺乳动物非胸腺硬终点的检索边界 20260427012501000
• 17-alpha estradiol 20260427012300000
• 长寿候选证据强度比较框架 20260427011842000
• rapamycin 严格复现审计应以协议元组而非药名抽象检索 20260427010925000
• rapamycin 复现审计的检索策略边界 20260427010327000
• rapamycin 的成年后寿命/健康寿命原始正例谱系 20260427010151000
• 局部 rapamycin 的硬终点审计空集 20260425221251000
• 局部 rapamycin 作为组织特异递送候选的证据边界 20260425220843000
• IL-11 pleiotropy audit should be split by terminal phenotype class 20260425211111000
• rapamycin 与自噬的单终点比较必须先收敛到共同最窄交集 20260425205350000
• rapamycin 与自噬的单终点比较门槛 20260425205231000
• rapamycin 的直接 organism-level 锚点 20260425204608000
• Iter-4360dd15-0098-EuropePMC-extract-human-trial-PMIDs 20260424212055000
• 先锁定综述正文里的表，再追原始试验 20260424175236000
• 先用综述表做骨架再回填原始试验 20260424174951000
• 先把异质证据拆成逐试验清单 20260424174404000
• 先抓人类试验证据表 20260424173558000